ストックスクリーナーアプリを入手
62.11
1.64%
-1.37
前日終値:
$63.48
開ける：
$62.44
24時間の取引高:
8,372
Relative Volume:
0.01
時価総額：
$2.67B
収益：
$451.36M
当期純損益:
$-66.42M
株価収益率:
-38.58
EPS:
-1.6097
ネットキャッシュフロー:
$-22.31M
1週間 パフォーマンス:
+1.88%
1か月 パフォーマンス:
+1.61%
6か月 パフォーマンス:
-22.43%
1年 パフォーマンス:
+45.28%
1日の値動き範囲:
$61.77
$62.44
1週間の範囲:
$61.38
$65.27
52週間の値動き範囲:
$38.51
$85.25
Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile
名前
Tarsus Pharmaceuticals Inc
セクター
電話
(949) 409-9820
住所
15440 LAGUNA CANYON ROAD, IRVINE
Compare TARS vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TARS
Tarsus Pharmaceuticals Inc
|
62.02 | 2.68B | 451.36M | -66.42M | -22.31M | -1.6097 |
VRTX
Vertex Pharmaceuticals Inc
|
437.34 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
642.22 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
804.77 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
300.05 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.46 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-24 | 再開されました | Oppenheimer | Outperform |
| 2025-12-09 | 開始されました | Barclays | Overweight |
| 2025-11-20 | 開始されました | Mizuho | Outperform |
| 2025-06-02 | 再開されました | Oppenheimer | Outperform |
| 2025-05-27 | 再開されました | H.C. Wainwright | Buy |
| 2023-11-20 | 開始されました | Goldman | Neutral |
| 2023-07-18 | 開始されました | William Blair | Outperform |
| 2023-05-18 | 開始されました | Guggenheim | Buy |
| 2022-08-01 | 開始されました | Barclays | Overweight |
| 2021-12-21 | 開始されました | H.C. Wainwright | Buy |
| 2021-11-23 | 開始されました | Oppenheimer | Outperform |
| 2020-11-10 | 開始されました | BofA Securities | Buy |
| 2020-11-10 | 開始されました | Jefferies | Buy |
| 2020-11-10 | 開始されました | Ladenburg Thalmann | Buy |
| 2020-11-10 | 開始されました | Raymond James | Strong Buy |
すべてを表示
Tarsus Pharmaceuticals Inc (TARS) 最新ニュース
Tarsus Advances TP-05 Lyme Prevention Trial, Setting Up a New Mid-Stage Catalyst for TARS Investors - TipRanks
John Cena hops into the ring to fight demodex blepharitis for Tarsus Pharmaceuticals - Medical Marketing and Media
Tarsus, RxSight Fall Despite Growth Signals - Orange County Business Journal
Precision Trading with Tarsus Pharmaceuticals Inc. (TARS) Risk Zones - Stock Traders Daily
Janus Henderson holds 2.24M shares in Tarsus Pharmaceuticals (TARS) - Stock Titan
Tarsus Q1 Review: Strong Earnings, But Wall Street Wanted A Guidance Raise (NASDAQ:TARS) - Seeking Alpha
Deep Track entities report 3.6M shares in Tarsus (NASDAQ: TARS) - Stock Titan
Did Tarsus’ (TARS) Surge in Q1 Revenue and Narrower Loss Just Shift Its Investment Narrative? - Sahm
Tarsus and John Cena Partner to Raise Awareness of Demodex - GlobeNewswire
Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans - Sahm
Number of shareholders of Tarsus Pharmaceuticals, Inc. – NASDAQ:TARS - TradingView
Number of shareholders of Tarsus Pharmaceuticals, Inc. – BX:TARS - TradingView
Assessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Weakness And Long Term Gains - Yahoo Finance
Is It Time To Reassess Tarsus Pharmaceuticals (TARS) After Its Recent Share Price Swings? - Yahoo Finance
Assessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Weakness And Pipeline Growth Expectations - Sahm
Lifesci Capital Has Negative Estimate for TARS Q2 Earnings - MarketBeat
What is HC Wainwright's Estimate for TARS Q2 Earnings? - MarketBeat
Tarsus Pharmaceuticals Earnings Call Signals Durable Growth - TipRanks
Vanguard Group Inc. Purchases 127,470 Shares of Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
Tarsus reiterates 2026 net product sales guidance of $670M-$700M as XDEMVY posts $145.4M in Q1 sales - MSN
Guggenheim Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $90 - Moomoo
Mizuho Securities Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $100 - Moomoo
Prudential subsidiaries hold 1.84M Tarsus shares (NASDAQ: TARS) - Stock Titan
A Quick Look at Today's Ratings for Tarsus Pharmaceuticals(TARS.US), With a Forecast Between $88 to $95 - Moomoo
Tarsus Pharmaceuticals Reports Revenue Increase in Q1 Driven by Xdemvy - VisionMonday.com
Tarsus Pharmaceuticals (TARS) Reports Strong Q1 2026 Earnings Dr - GuruFocus
Tarsus to Participate in Upcoming Investor Conferences - The Manila Times
Three Tarsus conference webcasts are set for May, with replays to follow - Stock Titan
Tarsus Pharmaceuticals, Inc. Q1 2026 earnings preview - MSN
Q1 2026 Tarsus Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q1 2026 Earnings Call Transcript - Insider Monkey
Tarsus Pharmaceuticals Q1 Earnings Call Highlights - MarketBeat
Tarsus Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:TARS) 2026-05-07 - Seeking Alpha
Tarsus Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Earnings call transcript: Tarsus Pharmaceuticals Q1 2026 beats EPS forecast, stock dips By Investing.com - Investing.com South Africa
Earnings call transcript: Tarsus Pharmaceuticals Q1 2026 beats EPS forecast, stock dips - Investing.com Nigeria
Tarsus Pharmaceuticals Inc (NASDAQ:TARS) Beats Q1 Estimates with Explosive XDEMVY Growth But Stock Slips - ChartMill
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Tarsus Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Tarsus (TARS) Q1 2026 Earnings Transcript - The Globe and Mail
Tarsus Pharmaceuticals (TARS) doubles revenue and trims quarterly loss - Stock Titan
Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements - The Manila Times
Jennison holds 1.71M shares in TARSUS PHARMACEUTICALS (TARS) — 4.0% - Stock Titan
XDEMVY drives strong Q1 2026 growth at Tarsus (TARS) - Stock Titan
BRIEF-Tarsus Pharmaceuticals Q1 EPS USD -0.16 - TradingView
H.C. Wainwright Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $88 - Moomoo
Technical Reactions to TARS Trends in Macro Strategies - Stock Traders Daily
Tarsus Pharmaceuticals Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView
TARS Reiterated by HC Wainwright & Co. -- Price Target Maintained at $88 - GuruFocus
D.A. Davidson & CO. Takes $1.49 Million Position in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
Jennison Associates LLC Sells 374,511 Shares of Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
Tarsus Pharmaceuticals Inc (TARS) 財務データ
収益
当期純利益
現金流量
EPS
2.25%
0.46%
大文字化:
|
ボリューム (24 時間):